Alzamend Neuro, Inc.
ALZN
$1.88
-$0.01-0.57%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 55.68% | -21.51% | 26.93% | 3.33% | -21.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.85% | -26.51% | 180.57% | 33.97% | -61.00% |
| Operating Income | -111.85% | 26.51% | -180.57% | -33.97% | 61.00% |
| Income Before Tax | -111.56% | 26.50% | -177.37% | -33.81% | 60.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -111.56% | 26.50% | -177.37% | -33.81% | 60.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.56% | 26.50% | -177.37% | -33.81% | 60.96% |
| EBIT | -111.85% | 26.51% | -180.57% | -33.97% | 61.00% |
| EBITDA | -111.77% | 27.87% | -181.40% | -34.50% | 61.29% |
| EPS Basic | 67.04% | 91.47% | 88.76% | 78.16% | 94.84% |
| Normalized Basic EPS | 65.98% | 91.47% | 88.76% | 85.62% | 95.00% |
| EPS Diluted | 67.04% | 91.47% | 88.76% | 78.16% | 94.84% |
| Normalized Diluted EPS | 65.98% | 91.47% | 88.76% | 85.62% | 95.00% |
| Average Basic Shares Outstanding | 521.68% | 761.62% | 2,368.93% | 829.80% | 680.61% |
| Average Diluted Shares Outstanding | 521.68% | 761.62% | 2,368.93% | 829.80% | 680.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |